Elekta (OTCMKTS:EKTAY) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research downgraded shares of Elekta (OTCMKTS:EKTAY) from a hold rating to a strong sell rating in a report issued on Tuesday,Zacks.com reports.

Elekta Price Performance

Shares of EKTAY stock opened at $5.63 on Tuesday. Elekta has a 12-month low of $4.35 and a 12-month high of $6.93. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -35.19 and a beta of 1.00. The company has a quick ratio of 0.73, a current ratio of 0.95 and a debt-to-equity ratio of 0.56. The firm has a fifty day moving average of $5.99 and a 200-day moving average of $6.02.

Elekta (OTCMKTS:EKTAY) last announced its quarterly earnings results on Thursday, May 28th. The company reported $0.06 earnings per share (EPS) for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 10.67%. The company had revenue of $521.00 million during the quarter. On average, equities research analysts forecast that Elekta will post 0.43 earnings per share for the current year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.